Azithromycin Use in Patients with GI Bleeding

Evidence-Based Safety Profile

The American Association for the Study of Liver Diseases recommends azithromycin as prophylactic antibiotic therapy in cirrhotic patients with acute GI hemorrhage to prevent bacterial infections and improve survival 1, 2, 3
Azithromycin can be substituted for quinolone antibiotics in cirrhotic patients with GI hemorrhage when oral administration is not possible or when quinolone resistance is a concern 1, 2, 3
The primary goal of antibiotic prophylaxis in cirrhotic patients with GI bleeding is to prevent bacterial infections, which occur in 25-65% of these patients and significantly increase mortality 2, 3
Antibiotic prophylaxis in cirrhotic patients with GI bleeding has been proven to decrease bacterial infection rates, reduce early rebleeding, and improve survival 1, 2

In cirrhotic patients with acute GI hemorrhage who cannot take oral quinolones, intravenous alternatives including azithromycin should be considered for infection prophylaxis 1, 2
For patients with advanced cirrhosis and GI hemorrhage, IV ceftriaxone has shown superior efficacy to oral norfloxacin in preventing bacterial infections, but azithromycin remains a reasonable alternative when ceftriaxone is unavailable or contraindicated 1

First-line antibiotic prophylaxis for cirrhotic patients with GI bleeding is norfloxacin 400 mg BID for 7 days, as recommended by the American Association for the Study of Liver Diseases 1, 2
Alternative oral options include ciprofloxacin, and IV alternatives include ceftriaxone and azithromycin 1, 2
The duration of prophylaxis is 7 days 1, 2

Patients with prior GI bleeding who are on anticoagulants, antiplatelet agents, NSAIDs, or corticosteroids should receive proton pump inhibitor (PPI) therapy regardless of azithromycin use, as recommended by the American Gastroenterological Association 4
PPIs reduce upper GI bleeding risk by 75-85% in high-risk patients and are superior to H2-receptor antagonists, according to the American College of Gastroenterology 5
History of peptic ulcer disease or prior GI bleeding is the strongest predictor of recurrent bleeding and warrants indefinite PPI therapy when patients remain on high-risk medications, as recommended by the American Gastroenterological Association 4, 5